Biomarker-Based Disease Detection Market is anticipated to surpass US$ 107.1 billion in 2031 at a CAGR of 11.0%

According to a research study published by Knowledge Sourcing Intelligence (KSI), the biomarker-based disease detection market will expand from USD 63.5 billion in 2026 to USD 107.1 billion in 2031 at a CAGR of 11.0% during the forecast period.

The market is expected to experience significant growth because of increasing needs for early disease detection and the development of precision medicine technologies.

Access sample report or view details: https://www.knowledge-sourcing.com/report/biomarker-based-disease-detection-market

Key Market Insight & Emerging Trends:

The biomarker-based disease detection market is expanding rapidly because biomarkers serve essential functions in diagnosing diseases, predicting their course, and monitoring how patients respond to treatment. The rising demand for personalized medicine, together with targeted therapies, has resulted in increased use of biomarker-based diagnostic methods.

The development of genomics, proteomics, and molecular diagnostics has reached a new level because next-generation sequencing (NGS) and immunoassays now provide better detection capabilities for biomarkers. The rising number of chronic diseases, which include cancer, cardiovascular disorders, and metabolic conditions, has led to greater demand for diagnostic tests that deliver precise results at an early stage.

The market expansion benefits from two main factors, which are the routine use of biomarker testing in clinical settings and the increasing research and development funding. The developing world experiences market growth because of its better healthcare systems and its citizens learning about modern diagnostic methods.

• North America maintained the highest market share during 2025 because its research capabilities enabled the quick implementation of new diagnostic technologies.

• The reagent and kit product category-controlled market share because these items remain essential for biomarker testing throughout time.

• The main technologies of the industry are immunoassays and NGS because they deliver precise results across multiple testing needs.

• The oncology field leads all other areas because cancer treatment needs biomarker testing at all stages.

The biomarker-based disease detection market operates as a competitive industry where top companies direct their efforts towards developing new products and forming partnerships to enhance their market standing.

Product Type Insights: Reagents & Kits Leading Market Consumption

The reagents and kits segment became the largest market segment in 2025 because biomarker-based tests require these consumables for their implementation. The market experiences continuous demand because diagnostic testing volume increases and clinical research applications expand.

Technology Insights: Immunoassays and NGS Driving Innovation

Immunoassays remain the preferred solution because they provide dependable results and affordable methods for identifying protein-based biological markers. The adoption of next-generation sequencing (NGS) technology is increasing because it provides precise analysis of complicated genetic markers, which doctors use for high-level diagnostic purposes.

Application Insights: Oncology Dominating the Landscape

Market leadership in oncology persists because medical professionals use biomarkers to detect tumors at their initial stages, assess patient danger levels, and track treatment results. The segment expansion receives momentum from two primary elements, which include the growing worldwide cancer incidence and the rising demand for targeted cancer treatments.

Regional Highlights: North America at the Forefront, Asia Pacific Accelerating

North America retained its market dominance in 2025 because of its developed medical system, substantial research funding, and wide use of biomarker diagnostic tests. The Asia Pacific region will experience the fastest growth rate throughout the forecast period because better medical services become available, while more diseases emerge, and governments establish precision medicine programs.

Competitive Landscape

As a part of the report, the major players operating in the pharmacogenomics testing market have been covered, such as Roche Diagnostics, Thermo Fisher Scientific, Illumina, Agilent Technologies, QIAGEN, Bio-Rad Laboratories, PerkinElmer, Diagenode, Active Motif, and Abcam. The companies allocate substantial funds towards research and development activities while they work to develop new biomarker tests and establish partnerships that will speed up their innovation process. The emerging companies in the industry concentrate on creating unique biomarker testing methods and diagnostic products.

Market Segmentation

The report segments the biomarker-based disease detection market as follows:

• By Product Type

  • Instruments

  • Reagents & Kits

  • Software & Services

• By Technology

  • Polymerase Chain Reaction (PCR)

  • Next-Generation Sequencing (NGS)

  • Microarrays

  • Mass Spectrometry

  • Immunoassays

• By Application

  • Oncology

  • Neurological Disorders

  • Autoimmune Diseases

  • Metabolic Disorders

  • Cardiovascular Diseases

• By Geography

  • North America

    • USA

    • Canada

    • Mexico

  • South America

    • Brazil

    • Argentina

    • Others

  • Europe

    • United Kingdom

    • Germany

    • France

    • Spain

    • Others

  • Middle East and Africa

    • Saudi Arabia

    • UAE

    • Others

  • Asia Pacific

    • China

    • India

    • Japan

    • South Korea

    • Indonesia

    • Thailand

    • Others

Companies Profiled:

• Roche Diagnostics

• Thermo Fisher Scientific

• Illumina

• Agilent Technologies

• QIAGEN

• Bio-Rad Laboratories

• vPerkinElmer

• Diagenode

• Active Motif

• Abcam

Explore More Reports:

• Cartilage Repair Market

• Biomarker-Based Disease Detection Market

• Huntington’s Disease Treatment Market